Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (Nasdaq: TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board").
***
December 6, 2023
2seventy bio, Inc.
60 Binney Street
Cambridge, MA 02142
Attention: Board of Directors
Dear Members of the Board:
Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareholder of 2seventy bio, Inc. (Nasdaq: TSVT) ("2seventy" or the "Company"), with an ownership position of approximately 3% of the Company's outstanding shares. According to its website, 2seventy is "inspired by the maximum speed of translating human thoughts into actions ? 270 miles per hour." For the shareholders you represent, 2seventy appears focused on the maximum speed it can destroy shareholder value ? taking just under 27 months to erase 93% of investors' capital.1 We fear much of this is due to the missteps taken by the Board and the Company's CEO Nick Leschly, who has a concerning track record of underperformance. As the former CEO of bluebird bio, Inc. (Nasdaq: BLUE), 2seventy's predecessor, Mr. Leschly raised more than $3 billion and vaporized this capital into a company with a market capitalization of around $450 million.
Today, 2seventy is at a crossroads. It has a cash balance of $284 million that is rapidly dwindling and a 50% profit interest in Abecma that is likely worth at least a few hundred million dollars. Despite this, the Company trades at a market capitalization of just $100 million.2 The reason for this wide disconnect is that the market attributes a steep negative value to the Company's cash-devouring development pipeline because it has lost faith in both the leadership and strategic direction of 2seventy.
In September, the Board announced a restructuring plan focused on the growth of Abecma that we do not believe goes far enough. At the same time, the Board announced Mr. Leschly's plan to step down as CEO and transition to Chairman of the Board, while promoting CFO Chip Baird to COO. At its current burn rate and assuming the Company cannot raise additional capital ? an appropriate and conservative assumption given the market environment and the Company's small market capitalization ? we believe 2seventy will run out of cash in 2025, destroying further shareholder value and putting patients at risk who rely on Abecma.
We believe there is a better way. Instead of daydreaming of hypothetical positive clinical data readouts from its pipeline (particularly two early-stage phase 1 trials3) that may give the Company a last gasp of capital, the Board needs to take the following actions today to protect, maximize and ensure the long-term viability of Abecma ? the Company's most valuable asset:
In conclusion, 2seventy's value creation opportunity is significant, but the Board must act with a sense of urgency to stop the cash burn, protect the balance sheet and the underlying value of Abecma. Unless the Board takes drastic measures along the lines we urge in this letter, we believe the Company will likely be bankrupt in a couple of years. Continuing on this path of value destruction is the ultimate example of corporate negligence and, should this be how you choose to proceed, we will pursue all options for holding each of you personally accountable.
We are requesting a meeting with members of the Board at your earliest convenience to discuss these aforementioned matters and initiatives. Our singular goal is to help put 2seventy back on the path to shareholder value creation as quickly as possible.
Sincerely,
Arnaud Ajdler
|
Managing Partner |
***
About Engine Capital
Engine Capital LP is a value-oriented special situations fund that invests both actively and passively in companies undergoing change.
1 2seventy was spun off from bluebird bio, Inc. on November 4, 2021, and its stock closed at $26.65 per share on that day.
2 2seventy and Bristol Myers Squibb share a 50% profit interest in Abecma; market capitalization based on $1.94 per share as of the close on December 1, 2023.
3 The bbT369 (NHL) and SC-DARIC33 (AML) programs.